DeuteRx is involved in improving medicines for patients. This description is self-described.

DeuteRx

Celgene Corporation is a biopharmaceutical company specializing in the development and commercialization of cancer and immunology drugs. Its major product is Revlimid (lenalidomide), used in the treatment of multiple myeloma and certain anemias.

Celgene Corporation

Poxel SA is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel SA

DeuteRx | 254 followers on LinkedIn. Devoted to improving patients&#39; lives and advancing small molecule therapies through Deuterium-Enriched Chiral Switching. | Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. 

DECS is a revolutionary strategy that stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy.

Life Sciences Executive & Serial Entrepreneur

Sheila DeWitt, PhD

Life Sciences CEO | Specializing in Early-stage Companies

Mike Webb

Founder, President, Chairman & CSO at RIFFIT

Lex Van Der Ploeg

Check out the results of our collaborative research effort with POXEL ! #PXL065 is the deuterium-stabilized (R)-enantiomer of pioglitazone and may be a safer and more effective NASH treatment than racemic pioglitazone. #NASH #NonAlcoholicSteatohepatitis #drugdiscovery #drugdevelopment #liverhealth #liverdisease #pioglitazone #DECS #DeuteriumEnabledChiralSwitching #DeuteRx #deuterium #racemic #enantiomer #innovationinhealthcare

Metric
Company Name	DeuteRx	Celgene Corporation	Poxel SA
Symbol
MSH ID	COM:DEUTERX	COM:CELGENE	COM:POXEL
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Biotechnology
Country	US		FR
Stage
Employee Count		10.00K
Website	deuterx.com	celgene.com	poxel.com
LinkedIn	deuterx		poxel
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DEUT

COM:DEUTERX

DeuteRx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue